Excessive accumulation of fat in the liver metabolic-associated fatty liver disease (MAFLD), is a common liver function abnormality, and obesity, diabetes mellitus, metabolic syndrome and cardiovascular disease are closely related to the negligence of fatty liver, may cause inflammation of the liver, liver fibrosis (scarring), cirrhosis, and severe It may lead to liver cancer or liver failure. As we all know the liver is a silent organ, there is no neural distribution, if the alarm signal, the situation has been serious, according to IQVIA (2023) reported that fatty liver patients continue to increase, estimated to affect the global population of about 25%, threatened to become a new threat to the health of the developed countries, and even more so, it is the focus of the metabolic health of the human body!

Over the past 40 years, patients with fatty liver had no cure, and could only be indirectly improved by diet and exercise, or related metabolic drugs such as hypoglycemic, antihypertensive, hypolipidemic, or hepatoprotective drugs, etc. Though this therapeutic area has attracted the investment of countless international pharmaceutical companies such as Novartis, Pfizer, or Gilead in the development of new drugs, due to the complexity of the disease-causing mechanism, all of them have failed miserably until the U.S. FDA approves a high standard of multifactorial, multi-metabolic pathways, multi-targets, multiple intercellular actions, and clinical endpoints on March 14, 2024, which is why all of them are failing miserably. However, due to the complexity of the disease-causing mechanism, which involves multi-factors, multi-metabolic pathways, multi-targets, multiple inter-cellular interactions, and high clinical endpoint standards, all of them failed miserably until March 14, 2024, when the U.S. FDA approved the world's first new drug for fatty liver to be listed on the market (trade name: RezdiffraTM, ingredient: Resmetirom, developer: Madrigal Pharmaceutical), which is a new drug for fatty liver and is currently under development. Pharmaceutical) for the treatment of steatohepatitis with moderate to advanced hepatic fibrosis, igniting hope in the long-dormant metabolic fatty liver disease drug cemetery, there are currently many potential new drug development competitors, with high-profile candidates in the pipeline, including those with Rezdiffra^TMViking Therapeutics' VK2809 has the same pharmacological mechanism, while another group of competitive dark horses belong to GLP-1 drugs (currently not approved for the treatment of fatty liver disease), such as Novo Nordisk's Semaglutide, Eli Lilly's Tirzepatide or MSD's Efinopegdutide, etc. Based on slowing down or stopping the development of liver fibrosis, this treatment field is regarded as a promising area to cure most chronic liver diseases. MSD's Efinopegdutide, etc., have the prospect of curing most chronic liver diseases based on delaying or preventing the occurrence of liver fibrosis, and thus this therapeutic area is regarded as a fast-emerging hot area for new drug development after new drugs for weight loss.